Clinical drug resistance of Enterobacteriaceae producing ESBLs bacteria
LI Juan1 DENG Qiu-lian2▲ LONG Yan2 HUANG Yu-jun2 SHANG Yan-yan1 YANG Li-na1
1.Clinical Laboratory,Affiliated Tumor Hospital of Guangzhou Medical University,Guangdong Province,Guangzhou 510095,China;
2.Clinical Laboratory,Women and Children Medical Center of Guangzhou City,Guangdong Province, Guangzhou 510623,China
Abstract：ObjectiveTo study the clinical drug resistance of Enterobacteriaceae producing ESBLs bacteria.Methods4265 strains of Enterobacteriaceae pathogenic bacteria in our hospital from July 2014 to September 2016 were selected, biological Meiliai analyzer was used for identification,after identification of ESBLs producing strain,drug sensitivity test was carried out to analyze the drug resistance of ESBLs producing bacteria in clinical antibiotics.ResultsAmong 4265 strains of Enterobacteriaceae,the ESBLs producing bacteria were mainly distributed in Proteus mirabilis,Klebsiella, Klebsiella pneumoniae and Escherichia coli.There were 2415 strains of ESBLs bacteria,the detection rate was 56.62%. The detection rate of ESBLs bacteria in pus,secretion,urine and bile in human body were higher.There was significant difference in the detection rate of ESBLs bacteria in different samples(P＜0.05).ESBLs producing bacteria were resistant to some antibiotics,most antibiotics were ineffective in producing ESBLs bacteria,while Imipenem was sensitive to ESBLs producing strains.ConclusionAmong the pathogenic bacteria of Enterobacteriaceae,ESBLs bacteria are the main bacteria,and most of antibiotics are ineffective,Imipenem is the last line of defense against ESBLs bacteria.It is suggested that antibiotics should be monitored before the clinical use of antimicrobial agents,and rational use of drugs according to the doctor′s advice is the main means to control and reduce the production of ESBLs bacteria.
京公网安备 11010502046607号